Bridge City Capital LLC Has $2.99 Million Stake in Krystal Biotech, Inc. $KRYS

Bridge City Capital LLC trimmed its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 14.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,135 shares of the company’s stock after selling 2,019 shares during the period. Bridge City Capital LLC’s holdings in Krystal Biotech were worth $2,992,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of KRYS. Bessemer Group Inc. grew its stake in Krystal Biotech by 106.9% during the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after buying an additional 77 shares in the last quarter. Sound Income Strategies LLC grew its stake in Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after buying an additional 127 shares in the last quarter. Greenline Wealth Management LLC acquired a new stake in Krystal Biotech during the fourth quarter worth about $34,000. Danske Bank A S acquired a new stake in Krystal Biotech during the third quarter worth about $35,000. Finally, UMB Bank n.a. grew its stake in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after buying an additional 37 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Krystal Biotech

In other news, EVP John Charles Thomas sold 642 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This trade represents a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

Krystal Biotech Trading Down 1.1%

KRYS stock opened at $317.97 on Friday. The stock has a market capitalization of $9.37 billion, a P/E ratio of 42.51 and a beta of 0.53. Krystal Biotech, Inc. has a 12 month low of $127.99 and a 12 month high of $331.49. The firm has a 50-day moving average price of $288.44 and a 200-day moving average price of $267.89.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. As a group, equities analysts predict that Krystal Biotech, Inc. will post 7.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of analyst reports. Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, April 9th. Wolfe Research initiated coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a “peer perform” rating on the stock. Guggenheim increased their target price on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. HC Wainwright reissued a “buy” rating and issued a $310.00 target price on shares of Krystal Biotech in a report on Monday, June 1st. Finally, Jefferies Financial Group increased their target price on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.